30390 Federal Register / Vol. 72, No. 104 / Thursday, May 31, 2007 / Notices 

Dated: May 22, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–10492 Filed 5–30–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 

Comment Request; The Jackson Heart 

Study (JHS) 

Summary: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Heart, Lung, and Blood Institute 

(NHLBI), the National Institutes of 

Health (NIH) has submitted to the Office 

of Management and Budget (OMB) a 

request for review and approval the 

information collection listed below. 

This proposed information collection 

was previously published in the Federal 

Register on October 25, 2006, pages 

62476–62477, and allowed 60 days for 

public comment. No comments were 

received. The purpose of this notice is 

to allow an additional 30 days for public 

comment. The National Institutes of 

Health may not conduct or sponsor, and 

the respondent is not required to 

respond to, an information collection 

that has been extended, revised, or 

implemented on or after October 1, 

1995, unless it displays a currently valid 

OMB control number. 

Proposed Collection: Title: The 

Jackson Heart Study (JHS). Type of 

Information Collection Request: 

Extension of a currently approved 

collection (OMB NO. 0925–0491). Need 

and Use of Information Collection: This 

project involves annual follow-up by 

telephone of participants in the JHS, 

review of their medical records, and 

interviews with doctors and family to 

identify disease occurrence. 

Interviewers will contact doctors and 

hospitals to ascertain participants’

cardiovascular events. Information 

gathered will be used to further describe 

the risk factors, occurrence rates, and 

consequences of cardiovascular disease 

in African American men and women. 

Frequency of Response: One time. 

Affected Public: Individuals or 

households; Businesses or other for 

profit; Small businesses or 

organizations. Type of Respondents: 

Individuals or households; Businesses 

or other for profit; not-for-profit 

institutions. The annual reporting 

burden is as follows: Estimated Number 

of Respondents: 600; Estimated Number 

of Responses per Respondent: 1.0; 

Average Burden Hours Per Response: 

0.5 and Estimated Total Annual Burden 

Hours Requested: 300. The annualized 

cost to respondents is estimated at 

$9,500. There are no Capital Costs to 

report. There are no Operating or 

Maintenance Costs to report. 

ESTIMATE OF ANNUAL HOUR BURDEN

Type of response Number of 

respondents 

Frequency of 

response 

Average time 

per response 

Annual hour 

burden 

Morbidity & Mortality AFU 3rd Party/Next-of-kin decedents ............................ 300 1 0.5 150 

Morbidity & Mortality AFU 3rd Party Physicians ............................................. 300 1 0.5 150 

Total .......................................................................................................... 600 ........................ ........................ 300 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, New Executive 

Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact: Ms. 

Cheryl Nelson, Project Officer, NIH, 

NHLBI, 6701 Rockledge Drive, MSC 

7934, Bethesda, MD 20892–7934, or call 

non-toll-free number 301–435–0451 or 

E-mail your request, including your 

address to: NelsonC@nhlbi.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

Dated: May 22, 2007. 

Peter Savage, 

Acting Director. 

Dated: May 22, 2007. 

Suzanne A. Freeman, 

Project Clearance Officer. 

[FR Doc. 07–2698 Filed 5–30–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Co-Exclusive 

License: Developing, Manufacturing 

and Selling Instruments, Reagents and 

Related Products and Providing 

Services Involving Sequencing Nucleic 

Acids, Including Without Limitations 

Diagnostic Devices and Services 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of a coexclusive license to practice the 

invention embodied in Patent 

Applications U.S. 60/151,580, filed 

August 29, 1999; PCT/US00/23736, filed 

August 29, 2000, U.S. 6,982,146 issued 

January 3, 2006, and USSN 11/204,367, 

filed August 12, 2005; entitled ‘‘High 

Speed Parallel Molecular Nucleic Acid 

Sequencing’’, to Invitrogen Corporation 

having a place of business in Carlsbad, 


sroberts on PROD1PC70 with NOTICES